SARS-CoV-2 Inactivated Vaccine

BIOLOGICAL5 trials

Sponsors

Pontificia Universidad Catolica de Chile, Sinovac Life Sciences Co., Ltd., Sinovac Research and Development Co., Ltd., PT Bio Farma

Conditions

COVID-19Covid19Vaccines

Phase 1

Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine

CompletedNCT05067894

PT Bio FarmaCovid19

Start: 2021-12-10End: 2022-08-06Updated: 2022-08-09

Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine Adjuvanted With Alum+CpG 1018

CompletedNCT05228613

PT Bio FarmaCOVID-19

Start: 2022-02-16End: 2023-01-24Updated: 2023-02-27

Phase 2

Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Children and Adolescents

CompletedNCT04884685

Sinovac Life Sciences Co., Ltd.COVID-19

Start: 2021-05-03End: 2022-06-20Updated: 2023-09-22

Phase 3

Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in Adults

CompletedNCT04651790

Pontificia Universidad Catolica de ChileCovid19, Vaccines

Start: 2020-11-27End: 2022-11-01Updated: 2023-02-02

Phase 4

Clinical Trial of Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults

Sinovac Research and Development Co., Ltd.COVID-19

Start: 2021-06-19End: 2021-12-19Target: 1400Updated: 2021-09-24

Related Papers

Differences in the immune response elicited by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial

eLife2022-10-1313 citations

SARS-CoV-2 vaccine booster in solid organ transplant recipients previously immunised with inactivated versus mRNA vaccines: A prospective cohort study.

2022-09-2318 citations

Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine

Frontiers in Immunology2021-09-2967 citations